Takeda Pharmaceutical Company Limited [NYSE: TAK] gained 2.15% or 0.36 points to close at $17.13 with a heavy trading volume of 2457253 shares. The company report on July 28, 2021 that U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1).
– If Approved, Investigational TAK-994 May Provide a Future Treatment Option Targeting the Orexin Deficiency Underlying NT1.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors. TAK-994 is currently being studied for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1),2 a chronic neurological disorder that alters the sleep-wake cycle.3 EDS is a hallmark symptom of NT1 and is characterized by a person’s inability to stay awake and alert throughout the day, and falling asleep unintentionally or at inappropriate times on a daily basis.3,4.
It opened the trading session at $16.84, the shares rose to $17.20 and dropped to $16.79, the range by which the price of stock traded the whole day. The daily chart for TAK points out that the company has recorded -2.39% loss over the past six months. However, it is still -11.96% lower than its most recent low trading price.
If we look at the average trading volume of 2.02M shares, TAK reached to a volume of 2457253 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Takeda Pharmaceutical Company Limited [TAK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TAK shares is $21.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TAK stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Takeda Pharmaceutical Company Limited shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 19, 2021. While these analysts kept the previous recommendation, Cowen raised their target price to Market Perform. The new note on the price target was released on November 01, 2019, representing the official price target for Takeda Pharmaceutical Company Limited stock.
The Average True Range (ATR) for Takeda Pharmaceutical Company Limited is set at 0.22, with the Price to Sales ratio for TAK stock in the period of the last 12 months amounting to 0.02. The Price to Book ratio for the last quarter was 0.01.
Trading performance analysis for TAK stock
Takeda Pharmaceutical Company Limited [TAK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.66. With this latest performance, TAK shares gained by 1.42% in over the last four-week period, additionally sinking by -2.39% over the last 6 months – not to mention a drop of -4.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TAK stock in for the last two-week period is set at 56.66, with the RSI for the last a single of trading hit 60.85, and the three-weeks RSI is set at 54.02 for Takeda Pharmaceutical Company Limited [TAK]. The present Moving Average for the last 50 days of trading for this stock 16.93, while it was recorded at 16.88 for the last single week of trading, and 17.45 for the last 200 days.
Takeda Pharmaceutical Company Limited [TAK]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Takeda Pharmaceutical Company Limited [TAK] shares currently have an operating margin of +17.18 and a Gross Margin at +58.77. Takeda Pharmaceutical Company Limited’s Net Margin is presently recorded at +11.76.
Return on Total Capital for TAK is now 5.49, given the latest momentum, and Return on Invested Capital for the company is 3.81. Return on Equity for this stock inclined to 7.60, with Return on Assets sitting at 2.92. When it comes to the capital structure of this company, Takeda Pharmaceutical Company Limited [TAK] has a Total Debt to Total Equity ratio set at 98.12. Additionally, TAK Total Debt to Total Capital is recorded at 49.53, with Total Debt to Total Assets ending up at 35.90. Long-Term Debt to Equity for the company is recorded at 96.72, with the Long-Term Debt to Total Capital now at 48.82.
Reflecting on the efficiency of the workforce at the company, Takeda Pharmaceutical Company Limited [TAK] managed to generate an average of $7,983,291 per employee. Receivables Turnover for the company is 4.00 with a Total Asset Turnover recorded at a value of 0.25.
Takeda Pharmaceutical Company Limited [TAK]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TAK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Takeda Pharmaceutical Company Limited go to 0.58%.
An analysis of insider ownership at Takeda Pharmaceutical Company Limited [TAK]
There are presently around $1,885 million, or 3.49% of TAK stock, in the hands of institutional investors. The top three institutional holders of TAK stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 18,717,144, which is approximately 117.182% of the company’s market cap and around 0.01% of the total institutional ownership; GLENVIEW CAPITAL MANAGEMENT, LLC, holding 16,104,222 shares of the stock with an approximate value of $275.87 million in TAK stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $93.13 million in TAK stock with ownership of nearly 1.385% of the company’s market capitalization.
Positions in Takeda Pharmaceutical Company Limited stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 155 institutional holders increased their position in Takeda Pharmaceutical Company Limited [NYSE:TAK] by around 22,205,868 shares. Additionally, 115 investors decreased positions by around 14,648,324 shares, while 77 investors held positions by with 73,193,637 shares. The mentioned changes placed institutional holdings at 110,047,829 shares, according to the latest SEC report filing. TAK stock had 47 new institutional investments in for a total of 3,981,523 shares, while 43 institutional investors sold positions of 1,681,106 shares during the same period.